Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum



Status:Completed
Conditions:Infectious Disease
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:7 - 90
Updated:5/27/2013
Start Date:November 2012
End Date:December 2014
Contact:Elizabeth L Hohmann, MD
Email:ehohmann@partners.org
Phone:617-724-7532

Use our guide to learn which trials are right for you!


Fecal microbiota transplantation (FMT) is the reconstitution of normal flora by a "stool
transplant" from a healthy individual to a C. difficile-infected recipient, and has long
been a successful approach to recurrent/refractory C. difficile. The purpose of this
project is to generate a frozen FMT inoculum from well-screened healthy volunteer donors
which can be used repeatedly, particularly in those who do not have a healthy intimate
partner or other related donor. Delivery of FMT has been performed colonoscopically, by
fecal retention enema, or by the nasogastric route. This study will evaluate the safety and
secondarily the efficacy of a frozen inoculum administered by nasogastric tube vs
administered by colonoscope.

Subjects with recurrent/relapsing C. difficile infection (10 per group) will receive FMT via
either:

- colonoscopy

- NGT

The primary endpoint is assessment of safety as measured by clinical events (GI, procedural,
systemic). Efficacy will be defined as a resolution of diarrhea off antibiotics for C.
difficile, in the absence of a need for OTHER systemic antibiotics, i.e. resumption of a
normal bowel status for the individual. Secondary efficacy endpoints include weight,
subjective well-being and relative clinical improvement per standardized questionnaire, and
subject qualitative assessment of, and satisfaction with, the transplant procedures.
Subjects will be monitored for clinical safety by history and standard exams and the
follow-up questionnaire as well as followed closely by phone and in person.


Inclusion Criteria:

- Patients with recurrent or relapsing CDI defined as EITHER(13):

- At least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper
with vancomycin with or without an alternative antibiotic (e.g. rifaximin,
nitazoxanide).

- At least two episodes of severe CDI resulting in hospitalization and associated
with significant morbidity.

- Willingness to accept risk of unrelated donor stool

- Willingness to be randomized to NGT vs. colonoscopic delivery.

- Able to consent for self, or parental assent/child assent as age appropriate.

Exclusion Criteria:

- Anatomic contraindication to NGT

- Delayed gastric emptying syndrome

- Known chronic aspiration

- Contraindication to colonoscopy (ASA 4 or more)

- High risk of bacterial translocation (Immunosuppression, cirrhosis etc)

- Pregnant or breastfeeding women

- Acute unrelated infection or comorbid illness exaccerbation
We found this trial at
1
site
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
?
mi
from
Boston, MA
Click here to add this to my saved trials